Arcturus Therapeutics

Yahoo Finance • 3 months ago

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154,... Full story

Yahoo Finance • 11 months ago

18 High Growth Low PE Stocks

In this article, we will take a detailed look at the18 High Growth Low PE Stocks. For a quick overview of such stocks, read our article 5 High Growth Low PE Stocks. When value stocks came back with a vengeance in 2022, value investors che... Full story

Yahoo Finance • last year

12 Best Healthcare Stocks For the Long-Term

In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare ind... Full story

Yahoo Finance • last year

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress

Expected cash runway extended to the end of 2026 $35 million milestone achieved under CSL collaboration ARCT-154 remains on track for Japan-NDA approval in December Enrollment target reached in Phase 3 bivalent COVID vaccine comparison... Full story

Yahoo Finance • last year

Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19

EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response compared to Comirnaty® and superiority of... Full story

Yahoo Finance • 2 years ago

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

KING OF PRUSSIA, Pa., Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arctur... Full story

Yahoo Finance • 3 years ago

Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their strong 147% return over the last three years

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. For instance the Arcturus Thera... Full story

Yahoo Finance • 3 years ago

CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO SAN DIEGO, May 05, 202... Full story

Yahoo Finance • 3 years ago

When Will Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Breakeven?

With the business potentially at an important milestone, we thought we'd take a closer look at Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) future prospects. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on... Full story

Yahoo Finance • 3 years ago

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

SAN DIEGO, March 25, 2022--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and... Full story